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Through a structure-based drug design project (SBDD), potent small molecule inhibitors of pyruvate 
carboxylase (PC) have been discovered. A series of α-keto acids (7) and α-hydroxycinnamic acids (8) 
were prepared and evaluated for inhibition of PC in two assays. The two most potent inhibitors were 
3,3′-(1,4-phenylene)bis[2-hydroxy-2-propenoic acid] (8u) and 2-hydroxy-3-(quinoline-2-yl)propenoic 
acid (8v) with IC50 values of 3.0 ± 1.0 μM and 4.3 ± 1.5 μM respectively. Compound 8v is a competitive 
inhibitor with respect to pyruvate (Ki = 0.74 μM) and a mixed-type inhibitor with respect to ATP, 
indicating that it targets the unique carboxyltransferase (CT) domain of PC. Furthermore, 
compound 8v does not significantly inhibit human carbonic anhydrase II, matrix metalloproteinase-2, 




Pyruvate carboxylase, Carboxyltransferase, α-Hydroxycinnamic acids, α-Keto acids 
1. Introduction 
Pyruvate carboxylase (PC) is an important anaplerotic enzyme that catalyzes the conversion of 
pyruvate to oxaloacetate (OAA) in a wide range of organisms.1 Studies have linked PC activity to a 
number of diseases and infections including certain types of cancer,2a type 2 diabetes,2b and 
listeriosis2c that are sustained as a result of aberrant or essential PC expression in cells. Genetic 
manipulations of PC have validated it as a potential target for the treatment of these diseases and 
infections, but genetic tools alone are insufficient to identify the precise mechanistic role that PC 
plays in vivo. Specific and potent small molecule effectors of PC can alter the catalytic activity without 
reducing or eliminating the gene product from the cellular system, thus precluding unintentional 
effects on associated metabolic and signaling enzymes in the cell. To date, attempts to use small 
molecule effectors to study PC directly in cellular studies have made use of unselective inhibitors of PC 
expression/activity, all of which have the potential to interact with multiple cellular systems.3 For 
example phenylacetate has been applied as a PC inhibitor in studies of insulin release.4 However, the 
high concentrations (>5 mM) required to partially inhibit PC are expected to impact many other cellular 
processes, including the induction of cell cycle arrest,5a,b and inhibition of nitric oxide synthase.5c 
The MgATP-dependent carboxylation of pyruvate by HCO3– to form OAA occurs in two distinct active 
sites of PC: the biotin carboxylation (BC) domain that is conserved across all biotin dependent 
carboxylases,6 and the unique carboxyltransferase (CT) domain that, outside of PC, is found in only a 
few bacterial oxaloacetate decarboxylases.7 The biotin cofactor, which is covalently attached to the 
biotin carboxyl carrier protein (BCCP) domain, is carboxylated in the BC domain, and subsequently 
transferred to the CT domain where pyruvate is carboxylated to form OAA. A structure-based project 
was initiated to develop chemical probes that will target the CT domain of PC. We describe here the 
discovery of promising first generation small molecule PC inhibitors and their kinetic characterization. 
2. Results and discussion 
Both substrates and inhibitors of the CT domain of PC can promote carboxybiotin 
decarboxylation.8 Binding of CT domain ligands facilitates a structural rearrangement which allows 
carboxybiotin to access the CT domain active site and decarboxylate.9 Fluoropyruvate (1a, Fig. 1), 
hydroxypyruvate (1b), oxamate (2) and glyoxylate (3) all promote carboxybiotin decarboxylation,8 and 
crystal structures of PC with pyruvate, 3-bromopyruvate (1c), oxalate (4), 1b, and 2 reveal that these 
molecules bind with overlapping orientations of their α-keto acid functional groups in the CT domain 
active site.10 
 
Fig. 1. Known inhibitors of pyruvate carboxylase. 
In parallel with efforts to screen compound libraries,11 we endeavored to identify inhibitors by taking 
the classical approach of modifying the enzymatic substrate. We reasoned that the range of known α-
keto acid PC inhibitors and their related X-ray structures would also support a structure-based 
approach that could help to identify larger α-keto acids inhibitors of PC, but with higher potency and 
selectivity. Our overall objective is to identify probes with suitable potency, selectivity and 
physico/physiochemical properties for in vivo studies. 
2.1. Compound synthesis 
Two routes were employed for the preparation of α-keto acids/substituted α-hydroxycinnamic acids 
(Scheme 1). Addition of one equivalent of a Grignard reagent to diethyl oxylate in ether/THF at −78 °C, 
followed by aqueous quench at low temperature afforded the corresponding α-ketoesters 5a-
b.12 Alternatively, heating a mixture of hydantoin and cyclohexane-carboxaldehyde or substituted 
benzaldehydes in ethanol/water afforded the corresponding 5-methylene-2,4-imidazolidinediones 6c-
u, which generally precipitated during the Knoevenagel condensation.13 Base hydrolysis of α-
ketoesters 5a-b or of 5-methylene-2,4-imidazolidinediones 6c-u gave the corresponding α-keto acids 
(7) or substituted α-hydroxycinnamic acids (8). 
 
Scheme 1. Syntheses of α-ketoacids/α-hydroxycinnamic acids. 
The parent, m- and p-substituted 3-arylpyruvic acids 8e, 8g-k, and 8m-v were found to exist 
predominantly in the enol form (i.e. α-hydroxycinnamic acid), while the alkyl substituted pyruvic 
acids 7a-c and the o-substituted 3-arylpyruvic acids 7f and 7l exist predominantly in the keto form. 
These assignments are based on NMR spectral data. In particular, signals at ca. δ 107 and at 
ca. δ 6.4 ppm (s, 1H) in the 13C and 1H NMR spectra of compounds 8 (in d6-DMSO) correspond to C3 
and its attached proton of the enol structures, while signals at ca. δ 30 and at ca. δ 3 ppm in the 13C 
and 1H NMR spectra of compounds 7 (in d6-DMSO) correspond to C3 and its attached proton of the 
keto structures. Similar keto-enol distribution has been previously observed in CD3CN.14 
2.2. PC inhibition assays 
While human PC represents the ideal target for these studies, it has proven to be extremely difficult to 
obtain workable yields of full-length, recombinant human PC.9a Instead, compounds were initially 
screened for inhibition of Staphylococcus aureus PC (SaPC) using an optimized fixed-time assay11 that is 
based on the reaction of OAA, the product of the PC-catalyzed reaction, with Fast Violet B (FVB), a 
diazonium salt which produces a colored adduct with an absorbance maximum at 530 nm (Scheme 2). 
 
Scheme 2. Detection of OAA production by reaction with FVB. 
As a secondary assay to confirm SaPC inhibition, the carboxylation of pyruvate in full-length SaPC was 
measured by coupling the formation of OAA to the reaction catalyzed by malate dehydrogenase 
(MDH), which converts OAA to malate and oxidizes NADH to NAD+ (Scheme 3). This can be readily 
observed by measuring the change in absorbance of NADH at 340 nm. 
 
Scheme 3. Detection of OAA production by a malate dehydrogenase (MDH) coupled enzyme assay. 
Compounds which existed predominantly as the α-keto acids (7a-d, Fig. 2; 7f and 7l, Table 1) as well as 
3-phenyllactic acid (9) had negligible inhibitory activity (IC50 > 1000 μM). In contrast, those compounds 
which existed as enols (α-hydroxycinnamic acids), such as phenylpyruvic acid (8e, IC50 = 240 μM, Table 
1), exhibited promising inhibitory activity in the FVB assay. The higher inhibition of enols over α-keto 
acids is consistent with the predicted pyruvate enolate intermediate in the CT domain reaction 
mechanism, suggesting that the high affinity of these compounds comes from their ability to serve as 
intermediate analogs. As such, these results are consistent with the CT domain as the target of these 
compounds. While α-hydroxycinnamic acid 8g bearing a strongly electron withdrawing para-nitro 
group exhibited only weak inhibitory activity, the corresponding α-hydroxycinnamic acid bearing 
a para-CF3 group (8k) inhibited pyruvate with IC50 = 130 μM in the FVB assay. There does not appear to 
be a strong correlation between the electron withdrawing/electron donating ability of para-
substituents and inhibitory activity. The two most potent inhibitors were 3,3′-(1,4-phenylene)bis[2-
hydroxy-2-propenoic acid] (8u) and 2-hydroxy-3-(quinoline-2-yl)propenoic acid (8v) with IC50 values of 
3.0 ± 1.0 μM and 4.3 ± 1.5 μM respectively. IC50 values determined in the MDH coupled assay were 
generally slightly lower than those determined in the FVB assay, but the values from these two assays 
correlated well. 
 
Fig. 2. Compounds which exist predominantly in the α-keto acid form (7a-7d) and 3-phenyllactic acid 
(9) exhibit weak inhibitor activity against SaPC (FVB assay). 




R2 R3 R4 FVB IC50 MDH IC50 
8e H H H 240 130 
7f NO2 H H >2000 >2000 
8g H H NO2 >1000 >1000 
8h H Me H 360 23 
8i H H Me 210 140 
8j H Me Me 98 38 
8k H H CF3 130 96 
7l Br H H >1000 >1000 
8m H H Br 200 81 
8n H H Cl 280 220 
8o H H F 100 30 
8p H H OMe 170 56 
8q H H OH 67 22 
8r H H 3-thienyl 48.0 – 
8s 
 
  58.6 – 
8t 
 
  118 – 
8u 
 
  3.0 ± 1.0 11 
8v 
 
  4.3 ± 1.5 3.2 ± 0.5 
 
2.3. Determination of mode of inhibition 
Steady-state kinetic analysis was used to determine the Ki value and mode of inhibition for one of the 
most potent compounds (8v). It was determined to be a competitive inhibitor with respect to pyruvate 
with a Ki = 0.74 μM, and a mixed-type inhibitor with respect to ATP with Ki = 5.2 μM (Fig. 3). As an 
additional measure to assess whether our procedure for determining Ki values was accurate, 
predictive Ki values were determined with the Cheng-Prussoff equation for competitive inhibition 
for 8v (0.46 μM) and oxalate (0.43 μM). The close match of the predictive and kinetically 
determined Ki values, as well as the unaltered binding affinity with increased concentration of ATP is 
consistent with direct competition of 8v with pyruvate in the CT domain active site. Identical modes of 
inhibition were observed against ATP and pyruvate for oxalate and for 8i, suggesting that α-
hydroxycinnamic acids specifically target the CT domain for inhibition (Supplementary Fig. S1). 
 
Fig. 3. Compound 8v is a competitive inhibitor with respect to pyruvate and a mixed-type inhibitor with 
respect to ATP. A) A double-reciprocal plot demonstrating competitive inhibition of 8v with respect to 
pyruvate, Ki value = 0.74 μM. B) A double-reciprocal plot demonstrating mixed-type inhibition 
of 8v with respect to ATP, Ki value = 5.2 μM. Initial velocities were determined at the following 
concentrations of 8v: 0 μM (circles), 1.5 μM (squares), 3 μM (upright triangles) and 6 μM (inverse 
triangles). The reported Ki values, α values and standard errors are determined from global fits of the 
data to the equations for reversible competitive or mixed-type inhibition. 
2.4. Docking studies 
Computational docking was conducted using the CT domain structure from S. aureus PC (pdb 
code 3BG5) to predict the relative binding affinity and poses of the most potent inhibitors for the CT 
domain of PC, and to visualize the predicted binding site. Upon the binding of pyruvate, the CT domain 
adopts a closed conformation where the carboxy moiety of pyruvate forms a salt bridge with the 
guanidinium side-chain of Arg644 (human PC numberings are used throughout) and the carbonyl 
oxygen of pyruvate is within hydrogen bonding distance of Arg571 and Gln575. These residues 
contribute to stabilizing the enolpyruvate intermediate. In the closed conformation, Tyr651 hydrogen 
bonds with Asp613.15 Due to the predicted importance of the enol moiety of the α-hydroxy-3-
arylcinnamic acids, all compounds were docked in their enol form. In the docking pose of 8u and 8v, 
with PC in the closed conformation, the carboxyl moieties are not positioned such that they form salt 
bridges with Arg644, but rather both are oriented such that the carboxyl groups are coordinated with 
the metal ion in the center of the CT domain active site (Fig. 4A and C). This interaction with 
Mn2+ contributes to an octahedral coordination, which is consistent with what has been observed in 
multiple crystal structures of PC. The carboxy moiety coordinated to the metal ion of both 8u and 8v is 
within hydrogen bonding distance of Arg571. Notably, docking studies predict both the α-enolic 
carboxyl moiety of 8u that is not predicted to coordinate the metal ion and the fused quinolinyl ring 
of 8v occupy the space that biotin has been shown to occupy in several X-ray crystal structures (see Fig. 
4B and D).9 
 
Fig. 4. A) Docking pose of 8u in the closed conformation of the CT domain without biotin present. The 
Mn2+ metal ion is represented by the grey sphere. B) Overlay of docked structure with the crystal 
structure showing the α-enolic carboxyl moiety of 8u that is not predicted to coordinate the metal ion 
occupies the binding location of biotin. C) Docking pose of 8v in the closed conformation of the CT 
domain without biotin present. D) Overlay of docked structure with the crystal structure showing the 
quinolinyl ring 8v occupies the binding location of biotin. Residues are numbered according to the 
sequence of human PC. 
2.5. Evaluation of 8u and 8v against hCAII, MMP-2, MDH and LDH 
The docking studies predicted that the α-keto acid moiety directly coordinates with the metal ion, 
raising questions about the selectivity of this class of compounds for PC inhibition. Selectivity was 
evaluated using two common metalloenzymes, human carbonic anhydrase 2 (hCAII) and matrix 
metalloproteinase 2 (MMP-2). While the potent PC inhibitor 8v did not appreciably inhibit hCAII at 
200 μM or MMP-2 activity at 50 μM (Fig. 5), compounds 8u and 8s increased the activity of hCAII, 
while 8u, 8s, and 8r exhibited substantial inhibition of MMP-2 at 50 μM. It is reassuring that 8v also did 
not inhibit enzymes that act on similar substrates: MDH (Supplementary Table S1, Supplementary Fig. 
S2) and lactate dehydrogenase (LDH) (Supplementary Fig. S2, Supplementary Fig. S3), nor is it used as a 
substrate of LDH (Supplementary Fig. S4). 
 
Fig. 5. Activity of human carbonic anhydrase II (hCAII = black bars) in the presence of compounds 
(200 μM) or matrix metalloproteinase-2 (MMP-2 = grey bars) in the presence of compounds (50 μM). 
(a) Negative control, (b) known inhibitor (acetazolamide, 5 μM for hCAII; PD166793, 100 μM for MMP-
2), (c) 8v, (d) 8u, (e) 8s, (f) 8r. Error bars represent standard error of the mean for four determinations 
each. 
3. Conclusions 
Building off the common binding motif observed for α-keto acids in the CT domain active site of PC, we 
synthesized and evaluated a series of α-hydroxycinnamic acids as a new class of PC inhibitors. 
Compared to previously characterized inhibitors of PC, these demonstrate improved potency and, 
for 8v, promising initial selectivity that serves as a good starting point for the continued development 
of small molecule probes directed against PC. Such probes will be enormously useful in evaluating the 
metabolic role of PC in the onset and progression of diseases such as type 2 diabetes and cancer. 
Future structure-based efforts will seek to further improve the design of molecular properties en route 
to producing the first class of potent and selective inhibitors of this important metabolic enzyme. 
4. Experimental 
4.1. Chemistry 
4.1.1. General experimental 
All reactions involving moisture or air sensitive reagents were carried out under a nitrogen atmosphere 
in oven-dried glassware with anhydrous solvents. THF and ether were distilled from 
sodium/benzophenone. Purifications by chromatography were carried out using flash silica gel (32–63 
μ). NMR spectra were recorded on either a Varian Mercury+ 300 MHz or a Varian UnityInova 400 MHz 
instrument. CDCl3 and d6-DMSO was purchased from Cambridge Isotope Laboratories. 1H NMR spectra 
were calibrated to 7.27 ppm for residual CHCl3 or 2.50 ppm for d5-DMSO. 13C NMR spectra were 
calibrated from the central peak at 77.23 ppm for CDCl3 or 39.52 ppm for d6-DMSO. Coupling constants 
are reported in Hz. Elemental analyses were obtained from Midwest Microlabs, Ltd., Indianapolis, IN, 
and high-resolution mass spectra were obtained from the COSMIC lab at Old Dominion University. 
Ethyl 2-oxo-5-hexenoate (5a)12a and ethyl 2-oxo-4-phenylbutanoate (5b)12b were prepared by literature 
procedures. Methyl 4′-formylcinnamate and methyl 3′-formylcinnamate were prepared by Pd-
catalyzed Heck coupling of methyl acrylate with either 4-bromobenzaldehyde or 3-
bromobenzaldehyde, and were identified by comparison to literature spectral data.16, 16(a) 4-(3-
Thienyl)benzaldehyde was prepared by Pd-catalyzed Suzuki coupling of 3-thiophene boronic acid with 
4-bromobenzaldehyde, and was identified by comparison to literature spectral 
data.16, 16(b) Phenylglyoxylic acid (7d), (2-nitrophenyl)pyruvic acid (7f), 2-hydroxy-3-(4-
hydroxyphenyl)-2-propenoic acid (8q) and 3-phenyllactic acid (9) were purchased from Sigma-Aldrich, 
and 2-hydroxy-3-(quinolin-2-yl)propenoic acid (8v) was purchased from Enamine Building Blocks. 
4.1.2. General procedure for hydrolysis of α-ketoesters 
To compounds 5a-b, a solution of excess 2.5 N NaOH was added. The aqueous mixture was stirred at 
room temperature until the initially emulsified mixture reached uniformity, at least 12 h. The reaction 
mixture was quenched with 1 N HCl, and the resulting α-keto acids were extracted several times with 
ether, and the combined organic layers washed with brine, dried (MgSO4) and concentrated to give the 
corresponding product 
4.1.3. 2-Oxohex-5-enoic acid (7a) 
The hydrolysis of 5a (60 mg, 0.38 mmol) by the general procedure gave 7a as a yellow oil (14 mg, 
29%). 1H NMR (400 MHz, CDCl3) δ 5.80–5.65 (m, 1H), 5.04–4.91 (m, 2H), 2.98 (t, J = 7.2 Hz, 2H), 2.44–
2.30 (m, 2H) 13C NMR (100 MHz, CDCl3) δ 195.1, 160.0, 135.8, 116.2, 36.7, 26.6 ppm. 
4.1.4. 2-Oxo-4-phenylbutanoic acid (7b) 
The hydrolysis of 5b (52 mg, 0.25 mmol) by the general procedure gave 7b as a yellow oil (29 mg, 
56%). 1H NMR (400 MHz, CDCl3) δ 7.33–7.17 (m, 5H), 3.21 (t, J = 7.6 Hz, 2H), 2.96 (t, J = 7.6 Hz, 2H); 13C 
NMR (100 MHz, CDCl3) δ 195.4, 161.1, 140.1, 128.6, 128.4, 126.4, 40.1, 29.0 ppm. The spectral data for 
this compound was consistent with the literature values.17 
4.1.5. General procedure for preparation of substituted 5-methylenehydantoins 
Hydantoin (500 mg, 5 mmol) was dissolved in H2O (50 mL) at 70 °C with stirring. Ethanolamine 
(0.61 mL) was added to the mixture, which was then heated to reflux. An equimolar quantity of the 
appropriate aldehyde solution (5 mmol in 5 mL ethanol) was added dropwise. The reaction mixture 
was heated at reflux for 5 h. The mixture was cooled to room temperature, during which time the 
product precipitated. The precipitate was collected via vacuum filtration, washed several times with 
H2O and dried in vacuo. Compounds 6c, 6e-i, and 6k-p were prepared by the procedure and their NMR 
spectral data was consistent with the literature values.13a 
4.1.6. 5-(3,4-Dimethylphenyl)methylene-2,4-imidazolidinedione (6j) 
Condensation of 3,4-dimethylbenzaldehyde (671 mg, 5.00 mmol) by the general procedure 
gave 6j (653 mg, 60%) as a white solid. mp > 215 °C; 1H NMR (400 MHz, d6-DMSO) δ 11.08–10.47 (br s, 
2H), 7.38 (s, 1H), 7.27 (d, J = 7.9 Hz, 1H), 7.10 (d, J = 7.9 Hz, 1H), 6.30 (s, 1H), 2.19 (s, 3H), 2.17 (s, 
3H); 13C NMR (100 MHz, d6-DMSO) δ 166.2, 156.1, 137.5, 137.2, 130.8, 130.4, 130.3, 127.7, 127.4, 
109.2, 19.7, 19.5 ppm. Anal. Calcd. For C12H12N2O2: C, 66.65; H, 5.59; N, 12.93. Found: C, 66.87; H, 5.54; 
N, 13.10. 
4.1.7. 5-[4-(3-Thienyl)phenyl]methylene-2,4-imidazolidinedione (6r) 
Condensation of 4-(3-thienyl)benzaldehyde (498 mg, 2.65 mmol) by the general procedure 
gave 6r (560 mg, 78%) as a beige solid. mp > 215 °C; 1H NMR (300 MHz, d6-DMSO) δ 8.28 (s, 1H), 7.93 
(s, 1H), 7.76 (d, J = 3.9 Hz, 1H), 7.74–7.70 (m, 2H), 7.64 (s, 1H), 7.62–7.57 (m, 2H), 6.34 (s, 1H); 13C NMR 
(75 MHz, d6-DMSO) δ 162.0, 157.3, 141.7, 135.6, 132.5, 130.3, 129.1, 128.1, 126.5, 122.6, 122.3, 107.9. 
4.1.8. 5-(4-(2-Methoxycarbonyl)ethenylphenyl)methylene-2,4-imidazolidinedione (6s) 
Condensation of methyl 4′-formylcinnamate (554 mg, 2.91 mmol) by the general procedure 
gave 6s (369 mg, 47%) as a pale yellow solid. mp > 215 °C; 1H NMR (400 MHz, d6-DMSO) δ 11.31 (s, 1H), 
10.69 (s, 1H), 7.67 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 8.0 Hz, 2H), 7.53 (d, J = 15.4 Hz, 1H), 6.55 
(d, J = 15.4 Hz, 1H), 6.37 (s, 1H), 3.53 (s, 3H); 13C NMR (100 MHz, d6-DMSO) δ 168.1, 165.9, 156.1, 
143.6, 135.2, 134.4, 130.2, 129.0, 128.3, 120.1, 107.8, 57.8. 
4.1.9. 5-(3-(2-Methoxycarbonyl)ethenylphenyl)methylene-2,4-imidazolidinedione (6t) 
Condensation of methyl 3′-formylcinnamate (537 mg, 2.44 mmol) by the general procedure 
gave 6t (409 mg, 53%) as a yellow solid. mp 232–235 °C; 1H NMR (400 MHz, d6-DMSO) δ 8.27–8.14 (m, 
1H), 7.84 (s, 1H), 7.77 (s, 1H), 7.59 (d, J = 16.4 Hz, 1H) 7.57–7.47 (m, 1H), 7.41 (t, J = 6.8 Hz, 1H), 7.25 
(t, J = 6.8 Hz), 6.65 (d, J = 16.4 Hz, 1H), 6.39 (s, 1H), 3.20 (s, 3H); 13C NMR (100 MHz, d6-DMSO) δ 166.3, 
165.8, 156.3, 139.0, 136.5, 134.0, 132.6, 129.8, 129.0, 127.2, 123.4, 121.7, 108.0, 60.3. HRMS (FAB): 
(M2 + Na+) found 567.1487. (C14H12N2O4)2Na requires 567.1486. 
4.1.10. 5,5′-(1,4-Phenylenedimethylidyne)bis[2,4-imidazolidinedione] (6u) 
Condensation of 1,4-benzenedicarboxaldehyde (671 mg, 5.00 mmol) by the general procedure was 
modified by the use of two equivalents of hydantoin (1.011 g, 10.10 mmol) gave 6u (442 mg, 30%) as a 
white solid. mp > 215 °C; 1H NMR (300 MHz, d6-DMSO) δ 10.89 (br s, 4H), 7.63 (s, 4H), 6.40 (s, 2H). 
4.1.11. General procedure for hydrolysis of benzylhydantions 
To a suspension of the benzylhydantoin in H2O (25 mL) was added solid NaOH (15 equivalents). The 
mixture was heated at reflux for 12 h under an N2 atmosphere, during which time the material went 
into solution. After cooling to room temperature, the stirred reaction mixture was quenched with 
concentrated HCl. The mixture was extracted several times with ether. The combined extracts were 
dried (MgSO4) and concentrated to give the α-keto acid/2-hydroxy-3-arylcinnamic acid. 
Compounds 7c, 7l14, 8e13c, 8g13d, 8h13c, 8i13c, 8k13f, 8n13f, 8o13e, 8p13f, were prepared by the procedure 
and their NMR spectral data was consistent with the literature values. 
The following compounds were prepared by this procedure: 
4.1.12. 3-(3,4-Dimethylphenyl)-2-hydroxy-2-propenoic acid (8j) 
Hydrolysis of 6j (424 mg, 1.99 mmol) by the general procedure gave 8j (206 mg, 55%) as an orange 
solid. mp 134–136 °C; 1H NMR (400 MHz, d6-DMSO): δ 9.90 (s, 1H), 7.60 (d, J = 7.6 Hz, 2H), 7.33 
(d, J = 7.6 Hz, 2H), 6.64 (s, 1H), 2.23 (s, 3H), 2.18 (s, 3H); 13C NMR (100 MHz, d6-DMSO) δ 167.0, 141.4, 
136.4, 136.0, 132.9, 130.8, 129.9, 127.4, 110.4, 19.9, 19.7 ppm. HRMS (FAB): M+Na+, found 215.0675. 
C11H12O3Na requires 215.0678. 
4.1.13. 3-(4-Bromophenyl)-2-hydroxy-2-propenoic acid (8m) 
Hydrolysis of 6m (403 mg, 1.51 mmol) by the general procedure gave 8m (99 mg, 27%) as a white solid. 
mp 194–196 °C; 1H NMR (400 MHz, d6-DMSO): δ 9.49 (s, 1H), 7.69 (d, J = 8.6 Hz, 2H), 7.51 (d, J = 8.6 Hz, 
2H), 6.36 (s, 1H); 13C NMR (100 MHz, d6-DMSO) δ 166.5, 143.1, 134.7, 131.7, 131.6, 120.5, 108.5 ppm. 
HRMS (FAB): M+Na+, found 264.9470. C9H7O3BrNa requires 264.9471. 
4.1.14. 2-Hydroxy-3-[4-(3-thienyl)phenyl]-2-propenoic acid (8r) 
Hydrolysis of 6r (493 mg, 1.83 mmol) by the general procedure gave 8r (49 mg, 13%) as a pale yellow 
solid. mp 194–196 °C; 1H NMR (400 MHz, d6-DMSO): δ 9.29 (s, 1H), 7.92 (q, J = 5.5 Hz, 1H), 7.87–7.83 
(m, 1H), 7.81 (s, 1H), 7.76 (d, J = 8.2 Hz, 2H), 7.20 (d, J = 8.2 Hz, 2H), 6.39 (s, 1H) 13C NMR (100 MHz, d6-
DMSO): δ 167.0, 142.5, 141.8, 134.5, 134.4, 130.6, 127.8, 126.7, 126.6, 121.7, 110.0. HRMS (FAB): 
M+Na+, found 269.0241. C13H10O2SNa+ requires 269.0243. 
4.1.15. 3-[4-(2-Carboxyethenyl)phenyl]-2-hydroxy2-propenoic acid (8s) 
Hydrolysis of 6s (369 mg, 1.34 mmol) by the general procedure gave 8s (43 mg, 14%) as a mustard 
brown solid. mp > 220 °C; 1H NMR (400 MHz, d6-DMSO): δ 9.55 (s, 1H), 7.75 (d, J = 8.6 Hz, 2H), 7.61 
(d, J = 8.6 Hz, 2H), 7.24 (d, J = 17.2 Hz, 1H), 6.45 (d, J = 17.2 Hz, 1H), 6.38 (s, 1H); 13C NMR (100 MHz, d6-
DMSO): δ 168.1, 166.5, 144.0, 143.2, 137.4, 130.0, 128.7, 128.5, 119.4, 108.9. HRMS (FAB): (M – H+) 
found 233.0453. (C12H10O5 – H+) requires 233.0455. 
4.1.16. 3-[3-(2-Carboxyethenyl)phenyl]-2-hydroxy2-propenoic acid (8t) 
From 6t (389 mg, 1.29 mmol), gave 8t (80 mg, 24%) as a yellow solid. mp 189 °C (dec.); 1H NMR 
(400 MHz, d6-DMSO): δ 9.41 (s, 1H), 7.94 (s, 1H), 7.82 (d, J = 7.7 Hz, 1H), 7.53 (d, J = 8.6 Hz, 1H), 7.50 (s, 
1H), 7.36 (t, J = 7.7 Hz, 1H), 7.22 (d, J = 16.1 Hz, 1H), 6.46 (d, J = 16.2 Hz, 1H), 6.40 (s, 1H); 13C NMR 
(100 MHz, d6-DMSO): δ 168.0, 166.6, 144.3, 143.0, 138.6, 136.2, 134.6, 131.1, 129.4, 127.1, 126.0, 
119.7. HRMS (FAB): (M + Na+) found 257.0421. C12H10O5Na+ requires 257.0420. 
4.1.17. 3,3′-(1,4-Phenylene)bis[2-hydroxy-2-propenoic acid] (8u) 
Hydrolysis of 6u (443 mg, 1.77 mmol) by the general procedure gave 8u (122 mg, 33%) as a dark yellow 
solid. mp 210 °C (dec.); 1H NMR (400 MHz, d6-DMSO): δ 9.29 (s, 2H), 7.69 (s, 2H), 7.14 (d, J = 8.0 Hz, 
2H), 6.35 (s, 2H); 13C NMR (100 MHz, d6-DMSO) δ 166.7, 142.4, 134.3, 129.6, 109.8. HRMS (FAB): 
M+Na+, found 273.0369. C12H10O6Na+ requires 273.0370. 
4.2. Enzyme inhibition assays 
4.2.1. Screening compounds for inhibition using Fast Violet B 
Compounds were initially screened for inhibition of S. aureus PC (SaPC) with an optimized assay that is 
based on the reaction of OAA, the product of the PC-catalyzed reaction, with Fast Violet B, a diazonium 
salt which produces a colored adduct with an absorbance maximum at 530 nm.11 The published 96-
well plate procedure was modified to a 384-well plate format such that all of the steps were identical 
except that the volumes were decreased by half to a final assay volume of 60 μL. Assay conditions 
consisted of 50 mM Bis-Tris (pH 7.7), 3 mM MgCl2, 150 mM KCl, 1% DMSO and 0.5% Triton x-100. To 
determine whether the compounds interfered with formation of the FVB-OAA colored adduct itself, 
the procedure was modified slightly: 15 μL of OAA was added to a final concentration of 200 μM in 
place of 15 μL enzyme. This functioned to assess for possible interference of the compounds with the 
formation of the FVB-OAA adduct. None of the described compounds interfered with the FVB assay 
signal at 200 μM (Supplementary Table S1). 
4.2.2. Measurement of OAA formation with malate dehydrogenase 
Malate dehydrogenase coupled enzyme assays were performed at 22 °C in a 96-well plate format for a 
total reaction volume of 200 μL. Assay conditions consisted of 100 mM Tris (pH 7.8), 7 mM MgCl2, 
150 mM KCl and 0.5% Triton x-100. First, 20 μL PC was added such that the final concentration in the 
assay was 10 μg/mL. Subsequently, 20 μL of compound was added to obtain the desired final 
concentration, 20 μL of MDH was added such that the final concentration in the assay was 20 U/mL, 
and lastly 140 μL of substrates were added to initiate the reaction (pyruvate, HCO3−, ATP and NADH to 
a final assay concentration of 12 mM, 25 mM, 2.5 mM and 0.25 mM, respectively). To assess the 
inhibition with respect to pyruvate, the procedure was modified such that 20 μL of pyruvate was added 
to the desired final concentrations prior to the addition of 120 μL of substrates to initiate the reaction 
(HCO3−, ATP and NADH to a final assay concentration of 25 mM, 2.5 mM and 0.25 mM, respectively). 
To assess the inhibition with respect to ATP, the procedure was modified such that 20 μM of ATP was 
added to the desired final concentrations prior to the addition of 120 μL of substrates to initiate the 
reaction (HCO3–, ATP and NADH to a final assay concentration of 25 mM, 12 mM and 0.25 mM, 
respectively). To account for possible compound inhibition of MDH (see Supplementary Table S1), the 
procedure was modified such that 20 μL OAA was added to a final concentration of 30 mM, in place of 
PC. Reagents were dispensed manually by a hand-held, multi-channel micropipette and absorbance 
measurements were recorded at 340 nm with a Multiskan Ascent spectrophotometer (Thermo). 
4.2.3. Evaluation against human carbonic anhydrase (hCAII) 
Assays for human carbonic anhydrase activity were performed in a 96-well plate format for a total 
reaction volume of 100 μL, in an assay modified from Day and Cohen.18 All assay reagents and solutions 
were prepared separately and maintained at 22 °C until warmed to 30 °C. All substrates, effectors, and 
enzyme were freshly dissolved and diluted in assay buffer containing 50 mM Tris (pH 8.0). The final 
concentration of the human carbonic anhydrase II enzyme was 200 nM. Where noted, acetazolamide 
was included at a final concentration of 10 μM. The substrate, p-nitrophenyl acetate, was added at a 
final concentration of 504 μM. For all experiments, 20 μL of enzyme stock solution was added to each 
well in a 96-well, flat-bottom, polystyrene microplate (Santa Cruz Biotechnology) followed by the 
addition of 10 μL of the effectors (assay buffer for the uninhibited reaction, acetazolamide for 
inhibition). The 96-well plate was then incubated in a plate reader at 30 °C for 10 min; concurrently, 
the substrate solution was also warmed to 30 °C for 10 min. The enzymatic reaction was initiated by 
adding 70 μL of the substrate solution (p-nitrophenyl acetate). The absorbance values were then 
measured at 405 nm every 30 s over a period of 20 min for a total of 40 measurements. 
4.2.4. Evaluation against matrix metalloproteinase-2 (MMP-2) 
Assays for human matrix metalloproteinase-2 activity were performed in a 96-well plate format for a 
total reaction volume of 100 μL, in an assay modified from Day and Cohen.18 All assay reagents were 
prepared and maintained at 22 °C until warmed to 37 °C. The omniMMP fluorogenic substrate and 
MMP-2 enzyme were prepared in assay buffer (50 mM HEPES, 10 mM CaCl2, 0.05% Brij-35, pH of 7.52), 
and small molecule effectors were prepared as a solution in 50% DMSO, 50% assay buffer. The final 
concentration of enzyme in the 100 μL enzymatic reaction was 0.0083 U/μL. A known inhibitor, N-[(4′-
bromo[1,1′-biphenyl]-4-yl)sulfonyl]-L-valine (PD166793), was included where noted at a final 
concentration of 100 μM. OmniMMP fluorogenic substrate was added to the 100 μL enzymatic 
reaction at a final concentration of 4 μM. For all experiments, 30 μL of enzyme stock solution was 
added to each well in a 96-well, flat-bottom, black polystyrene microplate (SantaCruz Biotechnology), 
followed by the addition of 10 μL of the effectors (50% assay buffer, 50% DMSO for the uninhibited 
reaction, PD166793 for inhibition). The 96-well plate was then incubated in a plate reader at 37 °C for 
30 min; concurrently, the substrate solution was also warmed to 37 °C for 30 min. The enzymatic 
reaction was initiated by adding 60 μL of the omniMMP fluorogenic substrate solution. The change in 
fluorescence was then monitored for 30 min with excitation and emission wavelengths at 320 and 
400 nm, respectively, every 46 s for a total of 40 measurements. 
4.3. Computational docking 
The ligand structures were built using ChemDraw (PerkinElmer) and saved as MDL Molefiles. The 
docking studies were performed using the docking program FITTED within the web-based FORECASTER 
platform,19 using the workflow “Docking-2D Molecules to a Rigid Protein (pdb)” which converts the 2D 
MDL Molefile to a 3D molecule and the protein pdb file (pdb code 3BG5) to a mol2 file. Protein 
Rotamer Elaboration and Protonation based on Accurate Residue Energy, or PREPARE, was utilized as 
part of the FITTED workflow. This software prepared all the atom files from the pdb files for suitable 
mol2 files. In addition to preparing the pdb files, PREPARE identified pyruvate in the pdb file by the 
residue name (PYR), chain location (A for open or C for closed conformation), and residue number 
(2001). The protein (as a mol2 file) was subsequently processed by PROtein Conformational Ensemble 
System Setup, or PROCESS, in the FITTED workflow to dock the 3D compounds in the binding site of the 
CT domain. The center of the binding site was defined by the center of pyruvate present in the active 
site. After the removal of pyruvate from the active site, a sphere with a radius of 15 Å was applied as 
the default for establishing the binding site cavity. FITTED utilized a genetic algorithm/hybrid matching 
algorithm to dock the compounds within the established cavity site. Docking scores were reported 
from FITTED as the predicted binding energy (ΔG) and, following computational docking, the lowest 
energy pose was visualized in Pymol. 
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